Zhongguo shi yan xue ye xue za zhi · 2025
[Relationship between the Expression of m6A Methyltransferase ZC3H13 Gene and the Clinical Features and Prognosis of Patients with Acute Myeloid Leukemia].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Jing, Ren Fang-Gang, Hao Zhuang-Hui, Wang Hong-Wei
Аннотация
OBJECTIVE: To explore the expression level of m6A methyltransferase ZC3H13 gene in primary acute myeloid leukemia (AML) and its relationship with clinical features and prognosis.
METHODS: A total of 131 newly diagnosed AML patients and 12 controls were enrolled from July 1, 2018 to December 1, 2021 in the Hematology Department of the Second Hospital of Shanxi Medical University. RT-qPCR technology was used to detect the expression level of ZC3H13 mRNA in bone marrow (BM) samples. A retrospective analysis was conducted to examine the correlation between ZC3H13 expression level and clinical indicators, gene mutations, and prognosis.
RESULTS: The expression level of ZC3H13 mRNA in primary AML patients was significantly higher than that in the control group ( P <0.001). The white blood cell count, proportion of BM blast cells, and relapse rate in the high ZC3H13 expression group were higher than those in the the low ZC3H13 expression group (all P <0.05), while the Th/Ts ratio was lower ( P <0.01). Univariate survival analysis showed that patients with high expression of ZC3H13 had shorter median overall survival (OS) and disease-free survival (DFS) than those with low expression of ZC3H13 (both P <0.05). The results of multivariate Cox regression analysis showed that high-risk stratification (OS:HR=1.612, 95% CI : 1.151-2.257, P =0.005; DFS:HR=1.551, 95% CI : 1.031-2.335, P =0.035) and high ZC3H13 expression (OS:HR=1.756, 95% CI : 1.028-2.999, P =0.039; DFS:HR=1.935, 95% CI : 1.018-3.678, P =0.044) were both independent risk factors for OS and DFS in AML patients.
CONCLUSION: The expression of ZC3H13 in AML patients may be related to tumor burden and immune function. Patients with high expression of ZC3H13 have poor prognosis, and high expression of ZC3H13 is an independent risk factor for the prognosis of AML patients.
METHODS: A total of 131 newly diagnosed AML patients and 12 controls were enrolled from July 1, 2018 to December 1, 2021 in the Hematology Department of the Second Hospital of Shanxi Medical University. RT-qPCR technology was used to detect the expression level of ZC3H13 mRNA in bone marrow (BM) samples. A retrospective analysis was conducted to examine the correlation between ZC3H13 expression level and clinical indicators, gene mutations, and prognosis.
RESULTS: The expression level of ZC3H13 mRNA in primary AML patients was significantly higher than that in the control group ( P <0.001). The white blood cell count, proportion of BM blast cells, and relapse rate in the high ZC3H13 expression group were higher than those in the the low ZC3H13 expression group (all P <0.05), while the Th/Ts ratio was lower ( P <0.01). Univariate survival analysis showed that patients with high expression of ZC3H13 had shorter median overall survival (OS) and disease-free survival (DFS) than those with low expression of ZC3H13 (both P <0.05). The results of multivariate Cox regression analysis showed that high-risk stratification (OS:HR=1.612, 95% CI : 1.151-2.257, P =0.005; DFS:HR=1.551, 95% CI : 1.031-2.335, P =0.035) and high ZC3H13 expression (OS:HR=1.756, 95% CI : 1.028-2.999, P =0.039; DFS:HR=1.935, 95% CI : 1.018-3.678, P =0.044) were both independent risk factors for OS and DFS in AML patients.
CONCLUSION: The expression of ZC3H13 in AML patients may be related to tumor burden and immune function. Patients with high expression of ZC3H13 have poor prognosis, and high expression of ZC3H13 is an independent risk factor for the prognosis of AML patients.